IDUA and mucopolysaccharidosis type 1: The first BBB Trojan horse fusion protein to enter clinical trials was a fusion protein of a MAb against the human IR (HIR), designated HIRMAb, and the lysosomal enzyme, α-L-iduronidase (IDUA), which is mutated in Type I Mucopolysaccharidosis (MPSI), and this HIRMAb-IDUA fusion protein is designated valanafusp alfa [2].